A review of evidence using Cochrane methodology and a literature review including follow up for at least three months. His conclusions are that there does seem to be a difference between CIN2 and CIN3. His conclusions were that active surveillance of CIN2 might be justified in selected women and if compliance is not likely to be an issue. If the changes persist for two years - treatment should be applied. Learn more by checking out thius video.
In this talk Pikka Niemminen provides a view from Finland regarding controversial issue of what to do with women with CIN 2.